Welcome to our dedicated page for Avant Technologies news (Ticker: AVAI), a resource for investors and traders seeking the latest updates and insights on Avant Technologies stock.
Avant Technologies Inc. (OTCQB: AVAI) issues frequent updates about its joint ventures, licensing agreements, and development programs in biotechnology and healthcare-focused artificial intelligence. Its news releases describe how the company is building a partnership-driven model around genetically modified cell lines, encapsulation technologies, and AI platforms that target chronic and age-related diseases.
Recent news has highlighted Avant’s joint venture with SGAustria Pte. Ltd. to form Insulinova, Inc., which is intended to develop cell-based therapies for type 1 and some insulin-dependent type 2 diabetes using insulin-producing cells combined with encapsulation technology. Other announcements cover the creation and progress of Klothonova, a 50/50 joint venture with Austrianova that is developing encapsulated Klotho-producing cell therapies for age-related conditions, including cardiovascular and neurodegenerative diseases.
Avant also reports on its collaboration with Ainnova Tech, Inc. through a joint venture that holds worldwide licensing rights to Ainnova’s Vision AI platform for early detection of diabetic retinopathy. News items describe regulatory interactions with the U.S. Food and Drug Administration, refinements to clinical trial protocols, and plans for patient recruitment in multiethnic populations at community and primary care sites.
Investors and observers following AVAI news can expect coverage of new joint venture agreements, updates on cell-based therapy programs, progress toward preclinical and clinical milestones, and developments in AI-based diagnostic initiatives. The company’s press releases also document corporate actions such as a proposed name change to Avaí Bio, Inc. and clarifications like the retraction of a previously announced but non-binding joint venture. This news feed allows readers to track how Avant’s partnership strategy evolves across its diabetes, longevity, and AI-driven healthcare efforts.
Avant Technologies (OTCQB: AVAI) announced that Vinicio Vargas, CEO of their joint venture partner Ainnova Tech, presented at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Colombia. The conference focused on scientific advances in treating common eye diseases and fostering regional collaboration.
Notably, Ainnova formed a strategic alliance with Roche and Salud 360 in Q4 2024 to launch a pilot program using their AI-powered Vision AI technology to combat diabetic retinopathy. If successful, the program could expand to the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights for Ainnova's technology portfolio.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have completed a crucial pre-submission meeting with the FDA regarding their Vision AI platform for early detection of diabetic retinopathy. The meeting provided essential guidance for their upcoming U.S. clinical trial, including protocol requirements and necessary resources.
Through their joint venture company Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights to Ainnova's technology portfolio, the companies are preparing to conduct data collection across U.S. primary care clinics. The study will compare their AI-based retinal screening against readings from three retinologists. The trial's success is crucial for obtaining FDA 510(k) clearance to market the technology in the United States.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have launched an innovative preventive care model in Latin America, focusing on diabetic patients. The model provides free retinal risk screenings at local pharmacies, shifting care from hospitals to convenient locations.
The initiative integrates key healthcare stakeholders including pharmacy chains, health clinics, insurance companies, and pharmaceutical partners. Ainnova's AI platform identifies at-risk patients before symptoms appear, enabling early intervention and better clinical outcomes.
Through Ai-Nova Acquisition Corp. (AAC), the companies hold worldwide licensing rights for Ainnova's technology portfolio. The company projects significant revenue growth for 2025 and 2026 as commercial agreements and pilot programs expand across multiple countries.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are preparing for a crucial FDA pre-submission meeting scheduled for July 7, 2025. The meeting will focus on discussing the planned clinical trial of Ainnova's Vision AI platform for early detection of diabetic retinopathy.
Through their partnership company Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights to Ainnova's technology portfolio, the companies aim to determine critical trial parameters including the number of clinical sites and total patients needed. The pre-submission meeting will be instrumental in obtaining FDA 510(k) clearance to market the Vision AI technology in the United States.
The technology aims to address diabetic retinopathy, the leading cause of preventable blindness worldwide, with potential applications in early detection of other conditions such as Alzheimer's and cardiovascular disease through retinal screening. The FDA engagement is considered crucial for entering the U.S. market and unlocking significant commercial potential.
Avant Technologies (OTCQB: AVAI) announced plans to establish a new company focused on diabetes treatment expansion. This development follows their successful joint venture with Ainnova Tech through Ai-nova Acquisition Corp (AAC), which utilizes the Vision AI platform for detecting diabetic retinopathy and other diseases.
The company's Vision AI technology can identify early markers of various conditions, including diabetic retinopathy, which affects over 30% of diabetes patients. With over 500 million people globally living with diabetes, Avant aims to expand from diagnosis to treatment through potential joint ventures, partnerships, or acquisitions.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are exploring the integration of early dementia detection into Ainnova's Vision AI platform. The companies are considering either licensing or acquiring a patented technology that uses AI algorithms and hardware for dementia detection through a 5-minute blood test.
The Vision AI platform currently employs 4 integrated algorithms to assess risks for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images, blood pressure, and lab test data. The system utilizes an automated, low-cost retinal imaging device for comprehensive preventive risk screening.
FAQ
What is the current stock price of Avant Technologies (AVAI)?
What is the market cap of Avant Technologies (AVAI)?
